Atossa Therapeutics (Atossa Therapeutics) 5-Year Dividend Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Atossa Therapeutics 5-Year Dividend Growth Rate?

Atossa Therapeutics's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Atossa Therapeutics's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Atossa Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Atossa Therapeutics's 5-Year Dividend Growth Rate

For the Biotechnology subindustry, Atossa Therapeutics's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atossa Therapeutics's 5-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's 5-Year Dividend Growth Rate falls into.

Atossa Therapeutics 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Atossa Therapeutics (NAS:ATOS) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Atossa Therapeutics's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-0.05
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atossa Therapeutics 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Atossa Therapeutics (Atossa Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (NAS:ATOS) » Definitions » 5-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

ATOS:Mexico YAG2:Germany

Address

107 Spring Street, Seattle, WA, USA, 98104

Website

https://www.atossatherapeutics.com

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Executives

Gregory L Weaver	director	185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Heather Rees	officer: SVP, Finance and Accounting	C/O ATOSSA THERAPEUTICS, INC., 107 SPRING STREET, SEATTLE WA 98104
Kyle Guse	officer: CFO & General Counsel	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. E SUITE 510, SEATTLE WA 98102
H. Lawrence Remmel	director	C/O ATOSSA GENETICS, INC., 4105 MADISON STREET, SUITE 320, SEATTLE WA 98112
Shu-chih Chen	director, 10 percent owner, officer: Chief Scientific Officer	C/O ATOSSA GENETICS, INC, 4105 E MADISON STREET, SUITE 320, SEATTLE WA 98112
Steven C Quay	director, 10 percent owner, officer: CEO	22026 20TH AVENUE S E, SUITE 102, BOTHELL WA 98021
Scott Youmans	officer: Chief Operating Officer	ATOSSA GENETICS INC., 2345 EASTLAKE AVE. E, SUITE 201, SEATTLE WA 98102
John E Sawyer	officer: See Remarks	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. E SUITE 510, SEATTLE WA 98021
Christopher S. Destro	officer: SVP, Sales and Marketing	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. EAST, SUITE 510, SEATTLE WA 98102
Peter J. Carbonaro	officer: Sr. Vice President, Operations	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. EAST, SUITE 510, SEATTLE WA 98102
Ben R Chen	officer: Sr. VP of Glob. Reg. Affairs	1616 EASTLAKE AVENUE EAST, SUITE 510, SEATTLE WA 98102
Richard I Steinhart	director	125 ELM STREET, NEW CANAAN CT 06840
Alexander D Cross	director	C/O LIGAND PHARMACEUTICALS INC.,, 10275 SCIENCE CENTER DR., SAN DIEGO CA 92121
Stephen J Galli	director	C/O ATOSSA GENETICS, INC., 4105 MADISON STREET, SUITE 320, SEATTLE WA 98112
John Barnhart	director	C/O ATOSSA GENETICS, INC, 4105 E MADISON STREET, SUITE 320, SEATTLE WA 98112